We found that high MAP17 levels are linked to bortezomib sensitivity in our adenocarcinoma cell lines, confirming these results for bortezomib and an alternative proteasome inhibitor in a publicly available database. The gene discussed is PDZK1IP1; the disease is adenocarcinoma.